Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Mol Cancer Ther January 1 2011 10 (1) 1-1;

Spotlight on Clinical Response

  • Spotlight on Clinical Response | Free Article
    Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
    Maria C. Villarroel, N.V. Rajeshkumar, Ignacio Garrido-Laguna, Ana De Jesus-Acosta, Siân Jones, Anirban Maitra, Ralph H. Hruban, James R. Eshleman, Alison Klein, Daniel Laheru, Ross Donehower and Manuel Hidalgo
    Mol Cancer Ther January 1 2011 10 (1) 3-8; DOI:10.1158/1535-7163.MCT-10-0893

Review

  • Review
    Notch Signaling Pathway as a Therapeutic Target in Breast Cancer
    Hamed Al-Hussaini, Deepa Subramanyam, Michael Reedijk and Srikala S. Sridhar
    Mol Cancer Ther January 1 2011 10 (1) 9-15; DOI:10.1158/1535-7163.MCT-10-0677

Therapeutic Discovery

  • Therapeutic Discovery
    Glutathione-Conjugate Transport by RLIP76 Is Required for Clathrin-Dependent Endocytosis and Chemical Carcinogenesis
    Sharad S. Singhal, Dilki Wickramarachchi, Sushma Yadav, Jyotsana Singhal, Kathryn Leake, Rit Vatsyayan, Pankaj Chaudhary, Poorna Lelsani, Sumihiro Suzuki, Shaohua Yang, Yogesh C. Awasthi and Sanjay Awasthi
    Mol Cancer Ther January 1 2011 10 (1) 16-28; DOI:10.1158/1535-7163.MCT-10-0699

  • Therapeutic Discovery
    Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth
    Huajun Zhao, Yuan-Hung Lo, Li Ma, Susan E. Waltz, Jerilyn K. Gray, Mien-Chie Hung and Shao-Chun Wang
    Mol Cancer Ther January 1 2011 10 (1) 29-36; DOI:10.1158/1535-7163.MCT-10-0778

  • Therapeutic Discovery
    Cell-Penetrating TAT-FOXO3 Fusion Proteins Induce Apoptotic Cell Death in Leukemic Cells
    Makram Essafi, Alice D. Baudot, Xavier Mouska, Jill-Patrice Cassuto, Michel Ticchioni and Marcel Deckert
    Mol Cancer Ther January 1 2011 10 (1) 37-46; DOI:10.1158/1535-7163.MCT-10-0482

  • Therapeutic Discovery
    Prediction of Colorectal Cancer Relapse and Prognosis by Tissue mRNA Levels of NDRG2
    Dake Chu, Zixi Zhang, Yunming Li, Lin Wu, Jing Zhang, Weizhong Wang and Jian Zhang
    Mol Cancer Ther January 1 2011 10 (1) 47-56; DOI:10.1158/1535-7163.MCT-10-0614

  • Therapeutic Discovery
    Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts
    Carly Griffin, Aditya Karnik, James McNulty and Siyaram Pandey
    Mol Cancer Ther January 1 2011 10 (1) 57-68; DOI:10.1158/1535-7163.MCT-10-0735

  • Therapeutic Discovery
    A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
    Hongbo Wang, Xujun Ma, Shumei Ren, John K. Buolamwini and Chunhong Yan
    Mol Cancer Ther January 1 2011 10 (1) 69-79; DOI:10.1158/1535-7163.MCT-10-0581

  • Therapeutic Discovery
    Therapeutic Targeting the Loss of the Birt-Hogg-Dubé Suppressor Gene
    Xiaohong Lu, Wenbin Wei, Janine Fenton, Michael S. Nahorski, Erzsebet Rabai, Anne Reiman, Laurence Seabra, Zsuzsanna Nagy, Farida Latif and Eamonn R. Maher
    Mol Cancer Ther January 1 2011 10 (1) 80-89; DOI:10.1158/1535-7163.MCT-10-0628

Preclinical Development

  • Preclinical Development
    A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma
    Sofía Torres, Mar Lorente, Fátima Rodríguez-Fornés, Sonia Hernández-Tiedra, María Salazar, Elena García-Taboada, Juan Barcia, Manuel Guzmán and Guillermo Velasco
    Mol Cancer Ther January 1 2011 10 (1) 90-103; DOI:10.1158/1535-7163.MCT-10-0688

  • Preclinical Development
    Chemopreventive and Chemotherapeutic Effects of Intravesical Silibinin against Bladder Cancer by Acting on Mitochondria
    Jin Zeng, Yi Sun, Kaijie Wu, Lei Li, Gang Zhang, Zenglei Yang, Zhiqiang Wang, Dong Zhang, Yan Xue, Yule Chen, Guodong Zhu, Xinyang Wang and Dalin He
    Mol Cancer Ther January 1 2011 10 (1) 104-116; DOI:10.1158/1535-7163.MCT-10-0577

  • Preclinical Development
    Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924
    Xiaonan Hou, Fei Huang, Joan M. Carboni, Karen Flatten, Yan W. Asmann, Cynthia Ten Eyck, Takeo Nakanishi, Jennifer D. Tibodeau, Douglas D. Ross, Marco M. Gottardis, Charles Erlichman, Scott H. Kaufmann and Paul Haluska
    Mol Cancer Ther January 1 2011 10 (1) 117-125; DOI:10.1158/1535-7163.MCT-10-0438

  • Preclinical Development
    ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action
    Graham C. Fletcher, Richard D. Brokx, Trisha A. Denny, Todd A. Hembrough, Stacy M. Plum, William E. Fogler, Carolyn F. Sidor and Mark R. Bray
    Mol Cancer Ther January 1 2011 10 (1) 126-137; DOI:10.1158/1535-7163.MCT-10-0574

  • Preclinical Development
    Celecoxib Can Induce Vascular Endothelial Growth Factor Expression and Tumor Angiogenesis
    Kaiming Xu, Huiying Gao and Hui-Kuo G. Shu
    Mol Cancer Ther January 1 2011 10 (1) 138-147; DOI:10.1158/1535-7163.MCT-10-0415

  • Preclinical Development
    Luteinizing Hormone-Releasing Hormone (LHRH)-I Antagonist Cetrorelix Inhibits Myeloma Cell Growth In vitro and In vivo
    Jianguo Wen, Yongdong Feng, Chad C. Bjorklund, Michael Wang, Robert Z. Orlowski, Zheng-Zheng Shi, Bing Liao, Jacqueline O'Hare, Youli Zu, Andrew V. Schally and Chung-Che Chang
    Mol Cancer Ther January 1 2011 10 (1) 148-158; DOI:10.1158/1535-7163.MCT-10-0829

  • Preclinical Development
    MEK/ERK Inhibitor U0126 Increases the Radiosensitivity of Rhabdomyosarcoma Cells In vitro and In vivo by Downregulating Growth and DNA Repair Signals
    Francesco Marampon, Giovanni Luca Gravina, Agnese Di Rocco, Pierluigi Bonfili, Mario Di Staso, Caterina Fardella, Lorella Polidoro, Carmela Ciccarelli, Claudio Festuccia, Vladimir M. Popov, Richard G. Pestell, Vincenzo Tombolini and Bianca Maria Zani
    Mol Cancer Ther January 1 2011 10 (1) 159-168; DOI:10.1158/1535-7163.MCT-10-0631

  • Preclinical Development
    Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
    Tomoyuki Nagai, Tokuzo Arao, Kazuyuki Furuta, Kazuko Sakai, Kanae Kudo, Hiroyasu Kaneda, Daisuke Tamura, Keiichi Aomatsu, Hideharu Kimura, Yoshihiko Fujita, Kazuko Matsumoto, Nagahiro Saijo, Masatoshi Kudo and Kazuto Nishio
    Mol Cancer Ther January 1 2011 10 (1) 169-177; DOI:10.1158/1535-7163.MCT-10-0544

  • Preclinical Development
    Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
    Stephane Dalle, Lina Reslan, Timothee Besseyre de Horts, Stephanie Herveau, Frank Herting, Adriana Plesa, Thomas Friess, Pablo Umana, Christian Klein and Charles Dumontet
    Mol Cancer Ther January 1 2011 10 (1) 178-185; DOI:10.1158/1535-7163.MCT-10-0385

  • Preclinical Development
    Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo
    Peter Jantscheff, Martin Schlesinger, Juliane Fritzsche, Lenka A. Taylor, Ralph Graeser, Gregor Kirfel, Dieter O. Fürst, Ulrich Massing and Gerd Bendas
    Mol Cancer Ther January 1 2011 10 (1) 186-197; DOI:10.1158/1535-7163.MCT-10-0474

  • Preclinical Development
    Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB Signaling Pathway
    Esther P. Jane, Daniel R. Premkumar and Ian F. Pollack
    Mol Cancer Ther January 1 2011 10 (1) 198-208; DOI:10.1158/1535-7163.MCT-10-0725

Molecular Medicine in Practice

  • Molecular Medicine in Practice
    Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Advanced Malignancies: A Phase I Clinical Trial
    Apostolia-Maria Tsimberidou, Chris H.M. Takimoto, Stacy Moulder, Cynthia Uehara, Monica Mita, Alain Mita, Patrick Urban, Eugene Tan, Yanfeng Wang, David Vining and Razelle Kurzrock
    Mol Cancer Ther January 1 2011 10 (1) 209-217; DOI:10.1158/1535-7163.MCT-10-0774

Back to top
PreviousNext
Molecular Cancer Therapeutics: 10 (1)
January 2011
Volume 10, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Issue Highlights

  • Glutathione-Conjugate Transport by RLIP76 Is Required for Clathrin-Dependent Endocytosis and Chemical Carcinogenesis

Jump to

  • Highlights
  • Spotlight on Clinical Response
  • Review
  • Therapeutic Discovery
  • Preclinical Development
  • Molecular Medicine in Practice
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • Targeted Delivery of MMAE Using Bicycle Molecules
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement